Lebed.biz Stock Profiles: December 14th, 2004: We are profiling Targeted Genetics Corp. (TGEN) at $1.79 as a speculative strong buy. TGEN develops gene therapy products and technologies for treating, both, acquired and inherited diseases. Its gene therapy product candidates are designed to treat disease by regulating cellular function at a genetic level, which involves introducing genetic material into target cells and activating the inserted gene. During the third quarter, TGEN completed patient enrollment in their AIDS vaccine Phase I clinical trial. TGEN continues to enroll patients in their rheumatoid arthritis Phase I clinical trial, and they also remain on track to complete enrollment of their Phase II cystic fibrosis clinical trial by the end of the year. This puts TGEN in a strong position to present data from these programs in the first half of 2005, on schedule with their goals. TGEN is a very exciting company and on any kind of positive trial results it could easily take off much higher. TGEN has been starting to trend higher during the past month and we believe it will have an exciting year ahead.